nach oben

vorheriger Artikel Practice-changing developments in early use of ...

nächster Artikel PD-1 and PD-L1 inhibitors after platinum-based ...

Tipp

Local therapy of stage IV renal cell cancer: a case report

Zeitschrift:: memo - Magazine of European Medical Oncology > Ausgabe 1/2018

Autoren:: Muna Ferner, Andrea Vera Keck, Dora Niedersüß-Beke, Kathrin Strasser-Weippl

Summary

This mini-review and case report demonstrates how systemic and local treatments work synergistically for patients with metastatic renal cell carcinoma (mRCC). Although new targeted and immunotherapies have revolutionized the treatment armamentarium of mRCC and dramatically improved patients’ prognosis, local treatment remains an important part of therapy. Here, we report on a patient who benefitted enormously from the combination and interaction of both therapeutic approaches, and we summarize the literature and guidelines that supported our treatment decisions in this case.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Jetzt einloggen Kostenlos registrieren

Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403. CrossRefPubMed

Flanigan RC, Yonover PM. The role of radical nephrectomy in metastatic renal cell carcinoma. Semin Urol Oncol. 2001;19(2):98–102. PubMed

Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70. CrossRefPubMed

Ulka N, Vaishampayan MD. The role of nephrectomy for kidney cancer in the era of targeted and immune therapies. Am Soc Clin Oncol Educ Book. 2016;35:e16–e20.

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(Supplement 5):v58. CrossRefPubMed

Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor—targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–9. CrossRefPubMed

Heng DY, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014;25(1):149–54. CrossRefPubMedPubMedCentral

Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med. 2014;370(18):1769–70. CrossRefPubMed

Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27(22):3584–90. CrossRefPubMedPubMedCentral

10.

Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28(6):1061–8. CrossRefPubMed

11.

Kavolius JP, Mastorakos DP, Pavlovich C, et al. Resection of metastatic renal cell carcinoma. J Clin Oncol. 1998;16(6):2261–6. CrossRefPubMed

12.

Alt AL, Boorjian SA, Lohse CM, et al. Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer. 2011;117(13):2873–82. CrossRefPubMed

13.

Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–422. CrossRefPubMed

14.

Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60. CrossRefPubMed

15.

Atzpodien J, Reitz M. Metastatic renal carcinoma long-term survivors treated with s. c. interferon-alpha and s. c. interleukin-2. Cancer Biother Radiopharm. 2005;20(4):410–6. CrossRefPubMed

16.

Albiges L, Oudard S, Negrier S, et al. Complete remission with tyrosine kinase inhibitors in renal cell carcinoma. J Clin Oncol. 2012;30(5):482–7. CrossRefPubMed

17.

Ornstein MC, Wood LS, Elson P, et al. A phase II study of intermittent Sunitinib in previously untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2017;35(16):1764–9. CrossRefPubMed

18.

Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449–56. CrossRefPubMed

19.

Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82. CrossRefPubMed

20.

Gibney GT, Aziz SA, Camp RL, et al. c‑Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343–9. CrossRefPubMed

21.

Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–97. CrossRefPubMed

22.

Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–27. CrossRefPubMed

23.

Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931–9. CrossRefPubMed

24.

Motzer RJ, Escudier B, Tomczak P, et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol. 2013;14(6):552–62. CrossRefPubMed

25.

Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015;33(13):1430–7. CrossRefPubMed

26.

Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advancedrenal-cell carcinoma. N Engl J Med. 2015;373:1803–13. CrossRefPubMedPubMedCentral

Titel: Local therapy of stage IV renal cell cancer: a case report
Autoren:: Muna Ferner
Andrea Vera Keck
Dora Niedersüß-Beke
Kathrin Strasser-Weippl
Publikationsdatum: 08.01.2018
DOI: https://doi.org/10.1007/s12254-017-0376-7
Verlag: Springer Vienna
Zeitschrift: memo - Magazine of European Medical Oncology An International Journal for Oncology and Haematology Professionals
Ausgabe 1/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076

Springer Medizin Österreich

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

My burning issues in TKI therapy and treatment-free remission in CML

Cell free nucleic acids as diagnostic and prognostic marker in leukemia

Practice-changing developments in early use of chemohormonal therapy in metastatic prostate cancer

Antiangiogenic therapies in ovarian cancer

Short overview on the current standard of treatment in newly diagnosed multiple myeloma

In need of special care: adolescent and young adult patients with cancer